Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birofen nasal spray, nasal steroid, and combination therapy in rhinitis
ChiCTR2200058263Phase 4Not yet recruiting
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of birofen in rhinitis, allergic rhinitis (AR), non-allergic rhinitis (NAR) and 1 more (4 arms), sponsored by Renmin Hospital of Wuhan University. Primary endpoint: Symptom score. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
birofen
03
Conditions
rhinitisallergic rhinitis (AR)non-allergic rhinitis (NAR)rhinosinusitis
Beyond the preview
Go deeper on ChiCTR2200058263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058263.